▶ 調査レポート

エキソソームの世界市場:分離方法別、下流分析別、用途別、地域別分析

• 英文タイトル:Global Exosomes Market - Segmented by Isolation Method, Downstream Analysis, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。エキソソームの世界市場:分離方法別、下流分析別、用途別、地域別分析 / Global Exosomes Market - Segmented by Isolation Method, Downstream Analysis, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-05193資料のイメージです。• レポートコード:B-MOR-05193
• 出版社/出版日:Mordor Intelligence / 2018年4月
• レポート形態:英文、PDF、108ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥629,000 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥666,000 (USD4,500)▷ お問い合わせ
  Corporate User¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、エキソソームの世界市場について調べ、エキソソームの世界規模、市場動向、市場環境、分離方法別分析、下流分析別分析、用途別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・エキソソームの世界市場インサイト
・エキソソームの世界市場環境
・エキソソームの世界市場動向
・エキソソームの世界市場規模
・エキソソームの世界市場規模:分離方法別
・エキソソームの世界市場規模:下流分析別
・エキソソームの世界市場規模:用途別
・エキソソームの世界市場:地域別市場規模・分析
・エキソソームの北米市場規模・予測
・エキソソームのアメリカ市場規模・予測
・エキソソームのヨーロッパ市場規模・予測
・エキソソームのアジア市場規模・予測
・エキソソームの日本市場規模・予測
・エキソソームの中国市場規模・予測
・エキソソームのインド市場規模・予測
・エキソソームの韓国市場規模・予測
・関連企業情報・競争状況

The global exosomes market is expected to register a CAGR of approximately 18.0% during the forecast period of 2018 – 2023. The exosomes play a vital role in cellular communication, which encapsulates several biomolecules including lipids, proteins, and nucleic acids. This market is driven by increasing research and development activities particularly for drug delivery, cancer immunotherapy, and diagnostics. As per the regional analysis, the rise in funding, a large base of clinical research organization and rise in the development of novel technologies through better healthcare infrastruture, helps North America to dominate the exosomes market.

Growing Prevalence of Cancer

The growing prevalence of cancer patients has a direct impact on the increased demand for the exosomes market. According to the 2012 report of the World Health Organization (WHO), there were 14 million new cases of cancer, which were expected to rise by about 70% over the next two decades. In the US, as per the National Cancer Institute report of 2018, an estimated 1.7 million of new cases of cancer I diagnosed in the country and nearly 0.6 million patients died from the diseases. Exosomes extracted from cow milk is being used for the delivery of therapeutic molecules against lung and breast cancer. Moreover, exosomes derived from specific sites of the body are promising candidates for the anti-cancer vaccines due to its enhanced passive targeting due to small size, indigenous nature, and the ability to cross the biological barriers. Thus, the increase in the cancer cases in the hospitals directly increases the demand for the need of exosomes in its diagnosis as well therapeutics.

Other driving factors include technological advancements in exosomes isolation and analytical procedures, growth in the government initiatives, and funding for exosome research with increased advanced applications for exosomes.

Technical Difficulties with the Implementation and Usage of Exosomes

The number of technical difficulties needs to be addressed for successful implementation of exosomes in various applications. This is one of the primary hinderances for the growth of the exosomes market. Some of the major difficulties include optimization of purification, increasing the homogeneity of exosomes, and efficient transfection strategies. This is further accompanied by lack of technical information like type rotor, diameter, volume, and viscosity of the sample, which restricts the maximum utilization of exosomes potential. Moreover, the cumbersome nature of methods for isolation/purification and inability to distinguish between different cancer stages with incomplete understanding on the immune system limits the market.

Other factors limiting the growth of this market are the lack of skilled professionals and stringent regulatory requirements for the approval and commercialization of exosomes products.

North America to Dominate the Market

North America is the region with a high degree of market lucrativeness. It is primarily due to the technological advancements, increased geriatric population coupled with an increase in the incidences of chronic diseases, such as cancer and cardiovascular diseases, with increased acceptance of exosome-based products. On the other side, the Asia-Pacific countries are expected to show wide opportunities for growth in development of exosomes related therapeutics and diagnostics with emerging economies, healthcare improvement in facilities particularly due to the involvement of private companies and collaboration with multinational players.

Key Developments in the Market

• January 2018 – ArunA Biomedical launched a new class of cell-free exosomes biologics to treat central nervous system and neurodegenerative disorders.
• September 2017 – PureTech Health PLC exclusively licensed novel milk-derived exosome technology, Calix, from 3P Biotechnologies, Inc.

Major players: DANAHER, DIAGENODE, INC., FUJIFILM HOLDINGS CORPORATION, HITACHI CHEMICAL DIAGNOSTICS, INC., LONZA, MBL INTERNATIONAL, MILTENYI BIOTEC, NOVUS BIOLOGICALS, QIAGEN, AND THERMO FISHER SCIENTIFIC, INC., amongst others.

Reasons to Purchase the Report

• Current and future of the global exosomes market outlook in the developed and emerging markets.
• Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
• The segment that is expected to dominate the market.
• Regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support, along with the Market Estimate sheet (in Excel).

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry
6. Market Dynamics
6.1 Drivers
6.1.1 Increasing Prevalence of Cancer
6.1.2 Technological Advancements in Exosomes Isolation and Analytical Procedures
6.1.3 Growth in Government Initiatives and Funding for Exosome Research
6.1.4 Increasing Advanced Applications of Exosomes
6.2 Restraints
6.2.1 Stringent Regulatory Requirement for Approval and Commercialization of Exosomes Products
6.2.2 Technical Difficulties with the Implementation and Usage of Exosomes
6.2.3 Lack of Skilled Professionals
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Isolation Method
7.1.1 Ultracentrifugation
7.1.2 Immunocapture on Beads
7.1.3 Precipitation
7.1.4 Filtration
7.1.5 Others
7.2 By Downstream Analysis
7.2.1 Cell Surface Marker Analysis through Flow Cytometry
7.2.2 Protein Analysis by Blotting & ELISA
7.2.3 RNA Analysis by NGS & PCR
7.2.4 Others
7.3 By Application
7.3.1 Drug Delivery
7.3.2 Tumor Immunotherapy
7.3.3 Diagnostic Biomarkers
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.1.4 Rest of North America
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Danaher
9.2 Diagenode, Inc.
9.3 Fujifilm Holdings Corporation
9.4 Hitachi Chemical Diagnostics, Inc.
9.5 Lonza
9.6 MBL International
9.7 Miltenyi Biotec
9.8 Novus Biologicals
9.9 Qiagen
9.10 Thermo Fisher Scientific, Inc.
9.11 *List not Exhaustive
10. Future of the Market
11. Disclaimer